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The carbohydrate-binding activity of the algal lectins from the closely related red marine algal species Bryothamnion triquetrum
(BTL) and Bryothamnion seaforthii (BSL) was used to diﬀerentiate human colon carcinoma cell variants with respect to their cell
membrane glyco-receptors. These lectins interacted with the cells tested in a dose-dependent manner. Moreover, the ﬂuorescence
spectra of both lectins clearly diﬀerentiated the cells used as shown by FACS proﬁles. Furthermore, as observed by confocal
microscopy, BTL and BSL bound to cell surface glycoproteins underwent intense internalization, which makes them possible
tools in targeting strategies.
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1.Signiﬁcance
To the best of our knowledge, this report is the ﬁrst
full investigation demonstrating composition diﬀerences in
cancer cell membranes detected by agglutinating proteins
from marine algae. In addition, according to our results,
Bryothamnion seaforthii (BSL) and Bryothamnion triquetrum
(BTL) lectins exhibit distinct proﬁles for the cell types
assayed. These diﬀerences could be due to the presence of
distinct glyco-receptors,d i ﬀerent levels of their expression on
the cell surface, or even by discrepancy in the aﬃnity proﬁle
of these lectins for these receptors.
2.Introduction
The carbohydrate-binding activity of lectins has been proven
to be responsible in promoting various cells, of diﬀerent
origins, to produce or mediate phenomena as distinct as
neutrophil adhesion and rolling during inﬂammatory
processes or nitric oxide induction in macrophages [1, 2].
Numerous lectins have become a powerful tool in the struc-
tural characterization of puriﬁed or membrane-attached
glycoconjugates, as well as in studies on cell behavior
[3–5].
The use of lectins in the therapy of many diseases has
been discussed elsewhere [6, 7], but this potential is still
far from being fully exploited. On the other hand, these
proteins have become well-established means for under-
standing various aspects of cancer and metastasis, given
that several studies have shown the modiﬁcation of surface
carbohydrates upon malignant transformation, tumor cell
diﬀerentiation, and metastasis [8, 9], and lectins are, in
several cases, good candidates for detecting such changes.
Theapplicationsproposedforlectinsinoncologyinclude
their use as diagnostic probes [10], biological response
modiﬁers (e.g., immunomodulatory eﬀects of the mistletoe
lectin ML-1 which result in dramatic antitumor eﬀect) and
as carriers for drug delivery and targeting [6, 11].2 Advances in Pharmacological Sciences
Marine algal lectins seem to be especially interesting for
biological applications, because they are in general, small
molecules (thus, thought to induce minor immunogenicity),
possess great stability on account of their several disulﬁde
bridges,andshowhighspeciﬁcityforcomplexcarbohydrates
and glycoconjugates, such as the ones present on cell surfaces
[12–14].
In the present study, we have combined ﬂow cytome-
try with confocal microscopy to examine glycoconjugates
expressed on cancer cell membranes and to discriminate
metastatic variants of human colon carcinoma cells, using
two marine algal lectins PITC-labeled, puriﬁed from the
red marine algae Bryothamnion seaforthii and Brythomnion
triquetrum, named BSL and BTL, respectively. Bovine serum
albumin (BSA) PITC-labeled was used as negative control in
the assays.
3.ExperimentalProcedures
Lectins. Puriﬁed BSL and BTL were obtained after ion ex-
change chromatography on a DEAE-cellulose column
according to the procedure described in references [15, 16].
The agglutinating fractions of each protein peak of both
algae were pooled, dialyzed, and lyophilized. The purity
was conﬁrmed by 12.5% SDS-PAGE [17]. PITC-labeling
(Molecular Probes, Inc) of the lectins was performed in
2.0mL of 0.1M carbonate/bicarbonate buﬀer, pH 9.3, and
ethylene glycol (3 : 1v/v), using a lectin/PITC ratio of
1 : 100. The mixture was submitted to constant mixing for
5h o u r s ,a t4 ◦C, in the dark. After incubation, the lectin-
PITC complex was separated from noncomplexed PITC by
molecular exclusion chromatography using a PD10 column
(Amersham Bioscience) equilibrated with water containing
5% N-butanol. The fractions containing the labeled-lectins
were recovered, dialyzed, and lyophilized.
Cells. The human colon adenocarcinoma cell line LS-
180 was obtained from Deutsche Krebsforschungzentrum,
Heidelberg, Germany. The LS 180 cells originated from a 58-
year-old Caucasian female with colon carcinoma Duke’s type
B.Thecellsproduceahighlevelofcarcinoembryonicantigen
(CEA) and express on their surface the tumor-associated
carbohydrate antigenic epitopes Lewis X, sialyl Lewis X, and
Lewis Y.
The endothelial cell line HPLNEC.B3—human micro-
vascular endothelial cells from a peripheral lymph node
of a patient with Hodgkin’s lymphoma—was isolated and
characterized, following procedures described in [18]. Cell
lines and the further selected variant sublines were grown
in OptiMEM medium supplemented with 3% fetal bovine
serum (all reagents from Gibco, Grand Island, N.Y.). Cells
were cultured in 25-cm2 T Cﬂ a s k sa t3 7
◦Ci na5 %C O 2-95%
humidiﬁed air (Falcon or Costar) atmosphere and passaged
weekly, using 0.25% trypsin/0.05% EDTA solution (Gibco,
Grand Island, N.Y.).
The in vitro selection of LS180 (EB3) cells with increased
aﬃnity for human HPLNEC.B3 microvascular endothelial
cells was carried out according to [19]. The EB3 variant
was subjected to further selection by inoculation in vivo, in
athymic NCr nu/nu male mice, by various routes of inoc-
ulation (intravenously, intrasplenically, or orthotopically),
to select diﬀerentially metastasizing variants [20]. After
repeated passages, several highly metastatic cells variants
were obtained. For the lectin binding experiments, LS 180,
EB3, and three variants were chosen: the ﬁrst variant,
LS-180EB3 5W (5W), metastasizes preferentially to the
liver, after orthotopic (into intestinal wall) transplantation;
the second one, LS-180EB3 3LNLN (3LNLN), metastasizes
to peripheral lymph nodes after intravenous inoculation,
and the third one, LS-180EB3 8W (8W) variant, forms
metastases in the liver, after intrasplenic inoculation. The
cells were propagated in OptiMEM medium supplemented
with 5% fetal bovine serum and 2mM glutamine (all
reagents from Gibco, Life Sci.) at 37
◦C, 5% CO2-95%
humidiﬁed atmosphere. The cells were cultured in 25-cm2
ﬂasks(Falcon)andlaterpassagedusing0.25%trypsin/0.05%
EDTA. Since Mycoplasma contamination of cell culture
systems causes major problems for basic research, samples
of each cell variant were screened for contamination with a
Mycoplasma detectionkitenzymeimmunoassay(Boehringer
Mannhaeim, Germany). The results were negative (data not
shown).
To choose the lectin concentration to be used in the
assays of lectin-cell-interaction, diﬀerent doses of each lectin
were initially evaluated (1, 2, 5, 10, 15, 20, and 25μg/mL).
For lectin-cell-interaction analysis, cells were collected
using 0.05% EDTA in 10mM phosphate-buﬀered saline, pH
7.4 (PBS), and suspended (2 × 105 cells) in 200μL of PBS
containing0.1%BSA.Thecellswereincubatedwithdiﬀerent
concentrations of PITC labeled-lectin in 200μL of PBS/0.1%
BSA for 1 hour at 4◦C, then centrifuged (1000 × gf o r5
min), and afterward washed to eliminate the noninteracting
PITC labeled-lectins. The cells were recovered in 1.0mL PBS
a n da n a l y z e di naF A C S C a l i b u rﬂ o wc y t o m e t e r( B e c t o n -
Dickinson). Live cells (5000 counts) were acquired for each
data ﬁle. The data were processed and the mean ﬂuores-
cence intensity was calculated by the Cell Quest Software
(Becton-Dickinson). The confocal microscopy analysis was
performed using aliquots containing 50000 cells in 250μL
PBS/0.1% BSA to which was added 150μL of PBS containing
lectin (25μg/mL for BODIPY-lectin binding and 10μg/mL
for PITC-lectin binding). The resultant material was then
divided into two glass tubes and incubated, separately, at 4◦C
and 37
◦C, for 45 minutes in the dark. After incubation, the
suspension was centrifuged (1500 × rpm) for 5 minutes at
4◦C. The supernatant was discarded, and the pellet recovered
in 100μL of PBS containing 1% paraformaldehyde; the cells
were then incubated for 45 minutes at room temperature.
After vortexing the cell suspension, an aliquot of 10μLw a s
placed on a glass slide and coverslipped. The interaction was
analyzed approximately 4 hours later, using a ZEISS Axiovert
S 100 microscope, with a confocal system, Bio-Rad MRC
1024, equipped with a 488-nm argon laser.
4. Results
The PITC-labeled algal lectins BSL and BTL were allowed
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Figure 1: Analysis by ﬂow cytometry of (a) Bryothamnion seaforthii lectin, BSL, and (b) Bryothamnion triquetrum lectin, BTL PITC, labeled.
In this assay lectins were used at 10μg/mL. (∗) negative control BSA PITC-labeled.
Table 1: Interaction of PITC-lectin complexes (expressed in ﬂuorescence units, FU∗) with human colon cancer cells.
Cell variant PITC-BSA∗∗ (10μg/mL) PITC-BTL∗∗∗ (10μg/mL) PITC-BSL∗∗∗ (10μg/mL)
LS 180 18.4 ± 0.9 6397.4 ± 287.8 5839.1 ± 280.3
EB3 21.1 ± 1.05 6904.7 ± 345.2 6599.3 ± 283.7
3LNLN 15.1 ± 0.75 3831.9 ± 180.1 4319.8 ± 215.9
5W 19.3 ± 0.96 3490.2 ± 143.1 3079.4 ± 141.6
8W 12.5 ± 0.68 6139.1 ± 288.5 5484.2 ± 213.9
∗Fluorescence detected by FACSort for a total of 5000 events (mean ± s.d.), corrected using standardization with Immuno-Brite (GIBCO).
∗∗BSA-PITC was used as negative control.
∗∗∗P < .05.
cell variants (3LNLN, 5W, and 8W). Analysis by ﬂow
cytometry demonstrated that both PITC-labelled proteins
were able to recognize cell membrane components in these
cells (Table 1). The recognition of cell surface components
indicates that these lectins were able to diﬀerentiate cancer
cell variants (Figure 1). The shift in ﬂuorescence intensity
induced by the interaction of the PITC-lectins with the
cell variants was quite similar, suggesting that the lectins
bound to the cell surface may be anchored by the same
component. It is interesting, however, that both lectins could
diﬀerentiate the cells tested under the same experimental
conditions. Analysis of the interaction, with regard to cell
recognition, showed that BSL and BTL discriminated the cell
variants.
Temperature variables (4◦Ca n d3 7
◦C) were used to
verify diﬀerences in the binding properties of PITC-lectins.
This step was necessary since the binding of the lectin to
the membrane elements is very likely to take place at 4◦C,
where the ﬂuidity of the cell membrane is reduced and the
energy consumed in the transport processes is limited. At
37
◦C, a strong interaction of the lectins with the glycocalix
components usually induces their uptake and storage in
acidic vacuoles such as the lysosomes [21]. The binding of
the lectins observed by ﬂow cytometry was conﬁrmed by
confocal analysis at 4◦C and no diﬀerences in the labeling-
patterns of BSL and BTL could be observed (Figure 2).
Nonetheless, when the bioadhesive activity was evaluated
at 37
◦C, some particularities were observed. In general,
internalization was quite evident (Figure 3).
5. Discussion
The haemagglutinating activity in extracts of the red marine
algae B.seaforthii and B. triquetrum was ﬁrst reported by
our group [22, 23]. Their agglutinating fractions mainly
recognized rabbit, chicken, and cow trypsin-treated ery-
throcytes. Puriﬁed BTL is an 8.9-kDa cysteine-rich protein
[16] and mono- di- and trisaccharides do not inhibit its
haemagglutinatingactivity[15].Thislatterpropertytogether
with the amino acid sequence [16] segregates these proteins
from the other groups of plant lectins, which are naturally
grouped on the basis of their monosaccharide speciﬁcity or
sequence homology. Since these proteins seem to possess
carbohydrate-binding speciﬁcity distinct from well-known
plantlectins, theyhaveemergedasanewtool to testdiﬀerent
activitiesalreadyinvestigatedusingplantlectins,especiallyin
the characterization of glycoconjugates.
According to our results, the two lectins exhibit distinct
proﬁles for the cell types examined. These diﬀerences could
be caused by the presence of distinct glycoreceptors, diﬀerent
levels of their expression on the cell surface, or still by
a discrepancy in the aﬃnity proﬁle of these lectins in
relation to these receptors. On the other hand, no signiﬁcant4 Advances in Pharmacological Sciences
(a) (b)
Figure 2: Confocal microscopy showing the interaction of (a) Bryothamnion seaforthii lectin, BSL, and (b) Bryothamnion triquetrum lectin,
BTL PITC, labeled (at 4◦C for 1 hour) with EB3 colon carcinoma cells variant. In this assay lectins were used at 10μg/mL. In each case the
lectin uptake was weakly visualized.
(a) (b)
Figure 3: Confocal microscopy showing the interaction of (a) Bryothamnion seaforthii lectin, BSL, and (b) Bryothamnion triquetrum lectin,
BTL PITC, labeled (at 37
◦C for 1 hour) with EB3 colon carcinoma cells variant. In this assay lectins were used at 10μg/mL. In each case the
lectin uptake was strongly visualized.
interaction was observed among the negative control (BSA)
and cells. BSA was added because it is a protein with
well-known physicochemical characteristics, without lectin
activity and that it is able of binding with PITC.
Unusual glycosylation of the cell surface proteins has
been frequently associated with the characteristics of malig-
nant cells. These include increased expression of Lewis-
related antigens, polylactosamine, and β-(1→6)GlcNAc
branching at the trimannoside core of the N-linked oligosac-
charides and structures of mucin-type O-linked glycans [24–
26]. Evidence has accumulated that some of these abnormal
glycosylations are important for tumor progression and
development of distant metastasis [27].
Abnormal glycosylations were also observed in mucins.
They are complex, carbohydrate-rich O-type glycoproteins
secreted by mucosal and submucosal glands and are thought
to act primarily as a physical/chemical barrier to pathogens
and particles [28, 29]. Mucins can be broadly classiﬁed as
e i t h e rs e c r e t e do rt r a n s m e m b r a n e .D i ﬀerential expression
of these glycoproteins has been correlated with malignant
transformation [30]. In fact, the expression of many cell
surface mucins is perturbed in colorectal neoplasia. MUC1
and MUC13, for instance, are highly expressed in such
carcinomas when compared to normal colon cells [17, 29].
It is well known that the glycoproteins mucins are strong
speciﬁc inhibitors of the hemaglutinating activity of lectins,
in particular those isolated from marine algae [12–15]. In
fact, mucin has been used as aﬃnity chromatography matrix
for lectin puriﬁcation [31], as well as inhibitor for biological
functions expressed by marine algae lectins [32–34].
Given the ability of both lectins presented here to bind to
mucins and based on the aforementioned data and on ours,
we speculate that one or both of these glycoproteins may be
the receptors recognized by BSL and BTL on the carcinoma
cells tested here.
The carbohydrate-binding activity of lectins has been
very useful in studying alterations in cell membrane glyco-
sylation, although the complexity of this problem could not
be tackled by a single approach. In fact, lectin binding to
carbohydrate-derivative self-assembled monolayers, showed
that the same lectins may switch from one carbohydrate
ligand to another as the surface density of the carbohydrate-
ligands increases [35]. This fact exposes the dimension and
complexity of the problem and suggests that to study or mapAdvances in Pharmacological Sciences 5
naturaloraberrantcellsurfaceglyco-receptors,notonebuta
set of well-characterized lectins with similar ligand capacity,
should be available.
It was observed that for both lectins the interactions with
diﬀerent cells increased proportionally with the diﬀerent
concentrations tested, until 10μg/mL. Above this concentra-
tion (10mg/mL), it can have saturation of the glycoconju-
gates recognized by the lectins. Thus, the interaction would
not increase when larger concentrations of lectins are used.
According to our results, BSL and BTL could be exploited
in investigating structural modiﬁcation of cell membrane
glycoconjugates on cell systems as we have tested in the
present study. However, more detailed investigations into
theirpreciseglycan-bindingspeciﬁcityshouldbecarriedout.
The diﬀerence in proﬁles shown by the highly similar
lectins BSL and BTL for the cell types studied is rather
common for legume lectins, which may show distinct bio-
logical activities despite their high similarity in both primary
sequence and overall three-dimensional structure [36]. In
fact, a previous study from our group has reported very
signiﬁcant diﬀerences in the ability of BSL and BTL lectins to
prevent streptococci adherence to acquired enamel pellicle in
vitro[33]. In addition, unpublished studies of ﬁne speciﬁcity
conducted by our group, show that BSL and BTL actually
exhibit distinct speciﬁcities for most glycoconjugates (e.g.,
bovine submaxillary mucin and porcine gastric mucin) that
were tested. Thus, we suggest that these punctual diﬀerences
in sequence reﬂect local alterations in the three-dimensional
structures. Such alterations are enough to cause a variable
carbohydrate aﬃnity, and may constitute the main cause for
the distinct proﬁle shown by BSL and BTL. Nevertheless,
this speculation hinges on the fact that the lectin-receptor
interaction is a protein-carbohydrate interaction, which
could not be demonstrated by inhibition assays in the lectin-
cell interaction system using classical plant lectin-inhibitory
saccharides, such as galactose, glucose, α-methylmannoside,
or lactose, as expected, given that there are no studies to date
reporting an algal lectin whose speciﬁcity is directed toward
mono- or disaccharides.
The biological signal transduction properties of lectins,
in general, appear to be due to their ability to bind and
then cross-link glycan receptors. This cross-linking leads to
changes in the interaction between receptor and cytoskeletal
proteins and concomitant alterations in the mobility and
aggregation of other surface events, including the ones
responsible for the internalization of BSL and BTL.
The ﬁnding that the binding of the lectins to the
carcinoma cells and the observation of its internalization are
quiteappealingsincetheycouldbeusedascarriersincancer-
targeted therapy [6]. There is evidence that drugs that bind
better to cancer cells than to normal ones are internalized
[37],butifthisdrugisboundtoalectinwhichisinternalized,
not only the speciﬁcity but the potency of the drug could be
enhanced.
In summary, we demonstrated that the algal lectins BSL
and BTL were capable of diﬀerentiating human colon carci-
noma cell variants with respect to their cell membrane glyco-
receptors and could be exploited to investigate structural
modiﬁcation ofcellmembraneglycoconjugatesincancercell
systems. In addition, we showed that the binding of both
lectins to the carcinoma cells results in their internalization,
which is a very interesting property that could be used in
future applications, such as drug delivery.
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